Tag: atogepant
-
AbbVie’s Qulipta Meets Phase 3 Goal in Menstrual Migraine
AbbVie’s Qulipta met the Phase 3 LUNA primary endpoint in menstrual migraine, reducing perimenstrual migraine days with a seven-day regimen timed to the onset of menses.
-
How Qulipta Blocks CGRP Signaling During the Menstrual Migraine Window
Estrogen withdrawal can increase migraine susceptibility around menstruation. Qulipta does not alter hormone levels; it blocks downstream CGRP receptor signaling during this predictable risk window.